LIFE SCIENCES AND HEALTHCARE INTRODUCTION India’s healthcare industry is worth around According to a recent study by PA Consulting for UK Trade & Investment, £25−30 billion and is expected to grow to the Indian healthcare sector has been growing at a CAGR of 14%. over £40 billion in the next two–three years. There is a huge demand−supply mismatch. 73.77 It is estimated that over 80,000 multi- speciality and super-speciality hospital beds are required. The UK businesses specialising 63.33 in the pharmaceutical, advanced healthcare delivery, diagnostics and medical equipment 53.6 and insurance segments have been successful in India. Other than expanding 44.21 opportunities in these segments, there 40.76 are opportunities in e-healthcare, clinical 38.14 research, R&D, education and training. 34.84 30.25 According to a study by an industry body and Ernst & Young, India will require another LIfe ScIenceS and 1.75 million beds by the end of 2025. The HeaLtHcaRe cOntact: public sector, however, is likely to contribute only around 15−20% of the required $86 Prasenjit Dhar, billion (approx. £53.75 billion) investment. [email protected] Corporate India is therefore leveraging this Tel: + 44(0)20 7592 3040 business potential and various healthcare 2005 2006 2007 2008 2009 2010 2011 2012 www.ukibc.com brands have started aggressive expansion in the country. Ranbaxy, Dabur, Apollo (est) (est) (est) (est) Hospitals, Fortis, Cipla and Wockhardt Source: PA Consulting study. are already household names and others planning to increase their footprint, According to a recent study including Anil Ambani’s Reliance Health, by PA Consulting for UK Trade the Hindujas, the Sahara Group, Emami, & Investment, the Indian Apollo Tyres and the Panacea Group. India’s healthcare industry is worth around £25−30 billion and is healthcare sector has been expected to grow to over £40 billion in the next two–three years. growing at a CAGR of 14%. +44(0)20 7592 3040 www.ukibc.com LIFE SCIENCES AND HEALTHCARE The rural healthcare sector is also expanding. The UK has a long history of working to help UKIBc annUaL SUMMIt 2011 The session participants were: The Rural Health Survey Report 2009, meet patient needs in India. Recent years At our annual summit, which took place • Sir Mark Walport, Director, released by the Ministry of Health, stated have seen an increase in the number of UK on 10th March in Manchester, we had a The Wellcome Trust that during the last ive years the rural health providers who can support healthcare projects session focusing speciically on opportunities sector has added around 15,000 health sub- in India, either by having operations in India and challenges facing the healthcare and • Dr Brian Tempest, Chairman, Religare centres and 28,000 nurses and midwives. or by having established partnerships with life sciences sector. The session considered Capital Markets (ex-Director, Ranbaxy) The report further stated that the number Indian irms to deliver cost-effective solutions. areas such as affordable healthcare • Jamila Joseph, Head of Clinical Research of primary health centres have increased Some of the key UK players already present technologies, biotech, and technology Services, Reliance Life Sciences by 84%, taking the number to 20,107. in the Indian market are GlaxoSmithKline collaboration and transfers suitable for the and AstraZeneca, as well niche companies • Dr Pawan Saharan, Founder According to an IBEF report, the key growth Indian market. Other than giving an overview such as Smith & Nephew, Huntleigh, the and CEO, Biomix driver for the Indian healthcare market is of opportunities that the Indian market Smiths Group, Randox Laboratories, Omega the increased spending on healthcare by presents, the experts on the panel talked of Diagnostics and Touch Bionics. We are also • Chris Francis, Founder, Cardionetics the growing middle class. It is expected their experience of and plans for working increasingly seeing investment in the UK that healthcare expenditure will grow at in Indian and UK markets and answered • Sujay Shetty, Partner, Head of and other global markets from major Indian around 15% annually. The sector is likely questions about doing business in India. Pharmaceutical Group, PwC India life science companies such as Reliance to contribute over 6% of India’s GDP and Life Sciences and TCG Life Sciences. employ around nine million people by 2012. The Rural Health Survey Report 2009, released by the Ministry of Health, stated that during the last ive years the rural health sector has added around 15,000 health sub-centres and 28,000 nurses and midwives. Source: Ernst and Young Research +44(0)20 7592 3040 www.ukibc.com LIFE SCIENCES AND HEALTHCARE Based on these arguments, the health up supplies as they battle falling prices (FTA) negotiations, India may have to MARKET UPDATE ministry advocates doing away with the and increasing generic competition. abide by a series of international standards current automatic 100% FDI approval route and regulatory practices in the healthcare for the pharmaceutical industry, suggesting Cipla, with a market value of $5.5 sector. For instance, EU negotiators have IndIan PHaRMaceUtIcaL SectOR that foreign investment in that sector should billion, is one of the world’s biggest sought India’s commitment to adopting GROWS at 16.5% In 2010 be allowed through the more controlled producers of low-cost antiretroviral Global Harmonisation Task Force (GHTF) and case-by-case FIPB (Foreign Investment norms for medical devices. The move The Indian pharmaceutical sector continued drugs to ight HIV and AIDS. its strong showing in 2010, growing at Promotion Board) route. However, at an comes at a time when India and other 16.5%. The £6.4 billion pharma market inter-ministerial meeting, the Finance Ministry Asian countries are trying to formulate has been on an upswing over the last four opposed changes to the current FDI policy for their own harmonised regulatory guidelines years, with annual growth of 13−17%, the pharma sector. Meanwhile, Commerce VIIV HeaLtHcaRe SeeKS PaRtneRS for medical devices because of divergent buoyed by strong demand, improved and Industry Minister Anand Sharma said fOR HIV dRUG In IndIa views on some of the GHTF standards. that FDI in new pharma projects would spending on healthcare and rising middle- In yet another attempt to drive down costs, India is also trying to align its rules with the continue and only those Indian companies class incomes. Industry experts expect the global drug maker ViiV Healthcare (a joint International Conference on Harmonisation that receive government funds for research trend to continue, with market growth for venture that houses the HIV/AIDS drugs (ICH) guidelines for drug regulators, , though could face a curtailment of their funding. 2011 forecast in the range of 15−17%. business of GlaxoSmithKline Pharmaceuticals not favouring simple adoption. Indian industry and Pizer, Inc.) is evaluating the scope sources say strict adherence to ICH guidelines MInIStRIeS deBate fdI In cIPLa In taLKS WItH GSK tO of local partnerships in India. One of the will help big pharmaceutical companies, but SUPPLY dRUGS potential organisations is Natco Pharma, prove to be a barrier for the growth of smaller PHaRMaceUtIcaLS which has sought a voluntary licence to make ones owing to the cost involved in such trials. Indian drug maker Cipla Ltd is said to be In pharmaceuticals, 100% foreign direct a low-cost version of the drugs. According to in talks with drug companies including investment (FDI) is permitted but there Viiv Healthcare, the local partners could be GlaxoSmithKline and Israel’s Teva to has been a debate within the Indian either for manufacturing or for marketing. HeaLtH InSURance PORtaBILItY government, the Ministry of Health and supply generic drugs. Cipla, India’s IntROdUced In IndIa second-largest pharmaceutical company If the deal goes through, this could Family Welfare arguing that acquisition The Indian insurance sector regulator by market value, has been in negotiations ultimately lead to the irst case in which a of Indian pharmaceutical companies by (IRDA) has approved a proposal to allow with GlaxoSmithKline for a few months compulsory drug licence is imposed for the multinationals could orient them away customers to switch health insurance policies for a number of speciic products. Indian domestic market. The controversial from the Indian market, thus reducing to an insurer of their choice. Though this provision under which the Indian government the domestic availability and increasing Cipla, with a market value of $5.5 billion, move is expected to provide customers can allow a generic drug maker to make the prices of the drugs they produce. The is one of the world’s biggest producers with more choice, market experts feel that a low-cost version of a patented drug by ministry is also concerned that takeovers of low-cost antiretroviral drugs to ight it is unlikely to lead to a signiicant fall in paying a fee is opposed by foreign drug might skew the market structure, which HIV and AIDS. The company provides premium rates. With rising medical costs makers, but is allowed under local laws. means a clutch of companies dictating AIDS drugs to African companies for just and a high inlation rate, most health prices of drugs that are critical for dealing $350 per year per patient, compared with insurers are just covering costs on their with public health concerns, including $10,000 charged by multinationals. tOUGH neGOtIatIOnS OVeR health portfolio